All Posts
EHRA consensus on prevention and management of interference due to medical procedures in patients with cardiac implantable electronic devices.
5 Apr, 2022 | 08:39h | UTCNews Release: Advice to prevent consequences of interference in cardiac device patients published today – European Society of Cardiology
RCT: Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D).
5 Apr, 2022 | 08:50h | UTCInvited Commentary: DNA vaccines join the fight against COVID-19 – The Lancet
Commentary on Twitter
DNA-based #COVID19 vaccine, ZyCoV-D, demonstrates efficacy, safety, and immunogenicity, according to interim analysis of phase 3 trial conducted in India.
More: https://t.co/bI2eXdbOvB pic.twitter.com/tMuHrA1kz6
— The Lancet (@TheLancet) April 2, 2022
EHRA practical guide: How to use digital devices to detect and manage arrhythmias.
5 Apr, 2022 | 08:41h | UTCHow to use digital devices to detect and manage arrhythmias: an EHRA practical guide – EP Europace
News Release: Advice on how to use digital devices to detect and manage arrhythmias published today – European Society of Cardiology
Review: Antiplatelet therapy after percutaneous coronary intervention.
5 Apr, 2022 | 08:38h | UTCAntiplatelet therapy after percutaneous coronary intervention – EuroIntervention
Commentary on Twitter
ANTIPLATELET THERAPY AFTER PCI: A State-of-the-Art review that summarises the evidence, and discuss current and future directions of antiplatelet treatment regimens after percutaneous coronary intervention. https://t.co/JyjvRTCz5e pic.twitter.com/T05SVBCmSb
— EuroIntervention (@EuroInterventio) April 1, 2022
M-A: Efficacy of interventions to reduce long term opioid treatment for chronic non-cancer pain.
5 Apr, 2022 | 08:29h | UTC
Expert Consensus Statement on the state of genetic testing for cardiac diseases.
5 Apr, 2022 | 08:31h | UTCNews Release: Recommendations on genetic testing for inherited cardiac diseases published today – European Society of Cardiology
Commentary on Twitter
#EHRA_ESC/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society Expert Consensus Statement on the state of genetic testing for cardiac diseases: https://t.co/CLL5EEuK6z#Europace #EHRA2022 @GerdHindricks @ABollmannMD #EPeeps #cardiotwitter pic.twitter.com/3hz4o5ynDh
— European Society of Cardiology Journals (@ESC_Journals) April 4, 2022
Cohort Study: Childhood cardiovascular risk factors and adult cardiovascular events.
5 Apr, 2022 | 08:23h | UTCChildhood Cardiovascular Risk Factors and Adult Cardiovascular Events – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Childhood cardiovascular risk factors including BMI, systolic blood pressure, lipid levels, and smoking were correlated with cardiovascular events in adulthood after a mean follow-up of 35 years. #ACC22 https://t.co/fh2SoQ09Qq pic.twitter.com/cZiYYGEubF
— NEJM (@NEJM) April 4, 2022
RCT: Efficacy and safety of Daprodustat (oral drug) for treating anemia of chronic kidney disease in incident dialysis patients.
5 Apr, 2022 | 08:34h | UTCRelated:
Commentary on Twitter
In this RCT, daprodustat was noninferior to darbepoetin alfa in treating anemia of chronic kidney disease. Daprodustat represents an oral alternative treatment to a conventional erythropoiesis-stimulating agent in the incident dialysis population. https://t.co/uoYOcpSam6
— JAMA Internal Medicine (@JAMAInternalMed) April 4, 2022
Review: The intensivist’s perspective of shock, volume management, and hemodynamic monitoring.
5 Apr, 2022 | 08:20h | UTC
Commentary on Twitter
https://twitter.com/CJASN/status/1511025812283092992
Podcast: Acute pancreatitis pearls.
5 Apr, 2022 | 08:26h | UTC#327 Acute Pancreatitis – The Curbsiders
Review: Patient-centered approaches for the management of unpleasant symptoms in kidney disease.
5 Apr, 2022 | 08:16h | UTC
Commentary on Twitter
In this Perspectives article, @kamkalantar and colleagues examine the concept & scope of symptom burden in #CKD, & discuss patient-centered approaches for the management of unpleasant symptoms in kidney disease https://t.co/ILBtWA3LTc pic.twitter.com/BYsoam1HeX
— Nature Reviews Nephrology (@NatRevNeph) January 25, 2022
Pericardial effusion and cardiac tamponade: pearls and pitfalls.
5 Apr, 2022 | 08:13h | UTCPericardial Effusion and Cardiac Tamponade: Pearls and Pitfalls – emDocs
Systematic Review: Prostatic arterial embolization for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.
5 Apr, 2022 | 08:10h | UTC
Systematic Review: Endovascular vs. conventional open surgical repair for thoracoabdominal aortic aneurysms.
5 Apr, 2022 | 08:11h | UTC
Commentary on Twitter
New #CochraneEvidence – are patient outcomes better after endovascular or open surgical repair of #thoracoabdominal #aorticaneurysm ? #TAAA #VascSurg https://t.co/7FEeqMOb5c @FutureVascSurgn @CochraneLibrary @CochraneUK @NIHRresearch @ESVSmembership @VSGBI @VascularSVS pic.twitter.com/GexAw2EYL5
— Vascular Evidence (@Vasc_Evidence) April 4, 2022
Systematic Review: Timing of antibiotic administration, wound debridement, and the stages of reconstructive surgery for open long bone fractures of the upper and lower limbs.
5 Apr, 2022 | 08:08h | UTC
RCT: Routine lung volume recruitment is not beneficial for boys with Duchenne muscular dystrophy.
5 Apr, 2022 | 08:04h | UTC
M-A of randomized trials: Effects of capecitabine as part of neo-/adjuvant chemotherapy in patients with breast cancer.
5 Apr, 2022 | 08:06h | UTCEffects of capecitabine as part of neo-/adjuvant chemotherapy – A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients – European Journal of Cancer (link to abstract – $ for full-text)
Review: Treatment strategies to improve outcomes in patients with chronic idiopathic constipation and irritable bowel syndrome with constipation.
5 Apr, 2022 | 08:00h | UTC
Review: Tackling the emerging threat of antifungal resistance to human health.
5 Apr, 2022 | 08:02h | UTCTackling the emerging threat of antifungal resistance to human health – Nature Reviews Microbiology (if the link is paywalled, try this one)
#ACC22 – 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure.
4 Apr, 2022 | 01:42h | UTCACC Guideline Hub: Heart Failure
Executive Summary: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
News Release: ACC, AHA, HFSA Issue Heart Failure Guideline – American Heart Association
Key Perspectives: 2022 AHA/ACC/HFSA Heart Failure Guideline
Slide Set Download: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Commentary on Twitter
New ACC/AHA/HFSA clinical guideline provides patient-centric recommendations for clinicians to prevent, diagnose, and manage patients with #HeartFailure.
Get the details in #JACC: https://t.co/zfbKMXxDNf#ClinicalGuidelines #HFrEF #CardioTwitter pic.twitter.com/hrvTj4TQUm
— JACC Journals (@JACCJournals) April 1, 2022
Cohort Study: Impact of myocardial injury after coronary artery bypass grafting on long-term prognosis.
5 Apr, 2022 | 08:03h | UTCRelated: Cohort Study: High-sensitivity Troponin I after cardiac surgery and 30-day mortality.
Commentary on Twitter
Revisiting the definition of perioperative myocardial infarction after coronary artery bypass grafting https://t.co/RnTrSZN96l @escardio #EHJ #ESCYoung #cardiotwitter @ehj_ed @rladeiraslopes pic.twitter.com/DvR3LX38ji
— European Society of Cardiology Journals (@ESC_Journals) March 30, 2022
#ACC22 – RCT: Treatment for mild chronic hypertension during pregnancy is associated with better pregnancy outcomes than a strategy of reserving treatment only for severe hypertension.
4 Apr, 2022 | 01:34h | UTCTreatment for Mild Chronic Hypertension during Pregnancy – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries:
Treating chronic hypertension in early pregnancy benefits parents, babies – NIH News Releases
CHAP: Better Blood Pressure Control, Better Pregnancy Outcomes – TCTMD
Commentary on Twitter
In pregnant women with mild chronic hypertension, targeting a blood pressure of < 140/90 mm Hg was associated with better pregnancy outcomes than a strategy of reserving treatment only for severe hypertension. #ACC22 https://t.co/fDrqa8uQiO pic.twitter.com/9KvogjnKcc
— NEJM (@NEJM) April 2, 2022
#ACC22 – RCT: Tranexamic acid reduces the risk of bleeding in patients undergoing noncardiac surgery.
4 Apr, 2022 | 01:37h | UTCTranexamic Acid in Patients Undergoing Noncardiac Surgery – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries:
POISE-3: Tranexamic Acid Stems Bleeding During Noncardiac Surgery – TCTMD
Commentaries on Twitter
HOT OFF THE PRESS:POISE-3 Tranexamic Acid
Incidence of composite bleeding outcome significantly lower with tranexamic acid vs placebo; between-group difference in composite CV outcome was small, but noninferiority of tranexamic acid was not established.https://t.co/FyuBliD0Mr— Steven Cohn, MD (@preopconsult) April 2, 2022
Among patients undergoing noncardiac surgery, the incidence of the composite bleeding outcome was significantly lower with tranexamic acid than with placebo. #ACC22 https://t.co/cYIQhE7YCD pic.twitter.com/l0QKgpEqnG
— NEJM (@NEJM) April 2, 2022
POISE-3 trial results showed a single dose of tranexamic acid before & after surgery significantly ⬇️ severe bleeding risk in pts undergoing noncardiac surgery compared w/ placebo. Findings could have global 🌏 impact, researchers said. https://t.co/LratgyadtE #ACC22 #cvSurg pic.twitter.com/HXlcp6bb0M
— American College of Cardiology (@ACCinTouch) April 2, 2022
WHO Strategic preparedness, readiness and response plan to end the global Covid-19 emergency in 2022.
4 Apr, 2022 | 01:44h | UTC
Commentary on Twitter (thread – click for more)
"WHO is releasing updated Strategic Preparedness, Readiness & Response Plan for #COVID19. This is our 3rd strategic plan for COVID-19, & it could & should be our last. It lays out 3️⃣ possible scenarios for how the pandemic could evolve this year"-@DrTedros https://t.co/ryb0QdlTqG
— World Health Organization (WHO) (@WHO) March 30, 2022
Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge (deliberately infecting individuals in a controlled environment) in young adults.
4 Apr, 2022 | 01:27h | UTCCommentaries:
Understanding COVID-19 through human challenge models – Nature Medicine
First human challenge study of Covid-19 yields valuable insights about how we get sick – CNN
First Human Challenge Trial Shows How COVID-19 Strikes – HealthDay
Related:
Scientists deliberately gave people COVID — here’s what they learnt.
World’s first coronavirus “Human Challenge” study receives ethics approval in the UK (several texts on the subject)
Commentary on Twitter
In the first #SARSCoV2 challenge study in humans, healthy adults were intranasally inoculated with virus and monitored for productive infection, symptoms, virus kinetics, antibody response and safety in a controlled setting @ChrisChiuLab #COVID19 https://t.co/b3H2ftaSFf
— Nature Medicine (@NatureMedicine) March 31, 2022


